Wall Street brokerages expect Transenterix Inc (NASDAQ:TRXC) to announce earnings of ($0.10) per share for the current quarter, according to Zacks. Three analysts have made estimates for Transenterix’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.09). Transenterix posted earnings of ($0.11) per share during the same quarter last year, which indicates a positive year over year growth rate of 9.1%. The business is scheduled to issue its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Transenterix will report full-year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.37). For the next year, analysts expect that the business will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.42) to ($0.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Transenterix.
Several equities analysts have recently issued reports on TRXC shares. Zacks Investment Research raised Transenterix from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a report on Wednesday, May 10th. B. Riley lowered Transenterix to a “neutral” rating and set a $0.70 target price for the company. in a report on Tuesday, May 16th.
Transenterix (TRXC) opened at 0.628 on Monday. Transenterix has a 52 week low of $0.45 and a 52 week high of $2.33. The stock’s 50 day moving average price is $0.68 and its 200 day moving average price is $0.95. The company’s market capitalization is $93.28 million.
TRADEMARK VIOLATION WARNING: This story was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://transcriptdaily.com/2017/08/13/transenterix-inc-nasdaqtrxc-expected-to-post-earnings-of-0-10-per-share-updated.html.
In other Transenterix news, Director Richard C. Pfenniger, Jr. bought 100,000 shares of Transenterix stock in a transaction dated Tuesday, May 16th. The stock was bought at an average cost of $0.54 per share, with a total value of $54,000.00. Following the completion of the acquisition, the director now directly owns 148,000 shares in the company, valued at approximately $79,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A hedge fund recently raised its stake in Transenterix stock. Global X Management Co. LLC boosted its stake in shares of Transenterix Inc (NASDAQ:TRXC) by 238.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 331,075 shares of the company’s stock after buying an additional 233,213 shares during the period. Global X Management Co. LLC owned approximately 0.22% of Transenterix worth $235,000 at the end of the most recent reporting period.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.